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ABSTRACT
Background Vein of Galen malformations (VOGMs)
are rare and complex congenital arteriovenous ﬁstulas.
The clinical and radiological features of VOGMs and
their relation to clinical outcomes are not fully
characterized.
Objective To examine the clinical and radiological
features of VOGMs and the predictors of outcome in
patients.
Methods We retrospectively reviewed the available
imaging and medical records of all patients with VOGMs
treated at the University of California, San Francisco
between 1986 and 2013. Radiological and clinical
features were identiﬁed. We applied the modiﬁed Rankin
Scale to determine functional outcome by chart review.
Predictors of outcome were assessed by χ2 analyses.
Results Forty-one cases were conﬁrmed as VOGM.
Most patients (78%) had been diagnosed with VOGM in
the ﬁrst year of life. Age at treatment was bimodally
distributed, with predominantly urgent embolization at
<10 days of age and elective embolization after 1 year
of age. Patients commonly presented with hydrocephalus
(65.9%) and congestive heart failure (61.0%). Mixed-
type (31.7%) VOGM was more common in our cohort
than purely mural (29.3%) or choroidal (26.8%) types.
The most common feeding arteries were the choroidal
and posterior cerebral arteries. Transarterial embolization
with coils was the most common technique used to treat
VOGMs at our institution. Functional outcome was
normal or only mildly disabled in 50% of the cases at
last follow-up (median=3 years, range=0–23 years).
Younger age at ﬁrst diagnosis, congestive heart failure,
and seizures were predictive of adverse clinical outcome.
The survival rate in our sample was 78.0% and
complete thrombosis of the VOGM was achieved in
62.5% of patients.
Conclusions VOGMs continue to be challenging to
treat and manage. Nonetheless, endovascular
approaches to treatment are continuing to be reﬁned
and improved, with increasing success. The
neurodevelopmental outcomes of affected children
whose VOGMs are treated may be good in many cases.
INTRODUCTION
Vein of Galen malformations (VOGMs) are arterio-
venous ﬁstulas hypothesized to arise in the fetal
period.1 VOGMs present antenatally, in early
infancy, or in childhood with signs and symptoms
ranging from high-output congestive heart failure
(CHF) and hydrocephalus to seizures and
intracranial hemorrhage.2 3 Before the advent of
surgical and endovascular embolization treatments,
VOGMs were universally associated with poor out-
comes.4–7 Historically, cases presenting neonatally
had mortality rates of 88–100% and those present-
ing in infancy or childhood had mortality rates of
40%.8
Endovascular embolization techniques have
reduced mortality and morbidity in patients with
VOGMs. The goals of endovascular treatment vary
depending on clinical presentation. Neonates with
CHF refractory to medical management are treated
urgently to establish hemodynamic stability and to
allow for heart and brain development.9 In neo-
nates without CHF, the goal of treatment is to
prevent cerebral venous hypertension, white matter
damage, and the “melting brain syndrome”. In
these cases, treatment is often deferred until the
child is aged 5–6 months to allow for greater cere-
bral maturation and enlargement of arteries usable
for therapeutic access.9 10 Studies have shown a
15% mortality rate in patients treated with endo-
vascular therapy, compared with 76.7% in
untreated patients and 84.6% in patients treated
with microsurgery.11–15
Despite these survival benchmarks, the clinical
outcomes of children treated with endovascular
techniques are not well characterized. After treat-
ment with earlier endovascular techniques, an esti-
mated 23–70% of children were neurologically
normal at short-term follow-up.11–13 16 17
Previously, a 2003 study at the University of
California at San Francisco (UCSF) showed favor-
able outcomes in 52% of all cases. The median dur-
ation of follow-up at that time was 4.5 years
(range=0.75–14 years for chart review). Poor out-
comes were associated with perinatal presentation,
the presence of CHF, and choroidal angioarchitec-
ture.17 Additionally, in the landmark Hospital
Bicetre series of 233 patients with VOGM, studied
between 1981 and 2002, 143 (74%) of 193 survi-
vors were reported to be neurologically normal on
last reported follow-up.10 Other studies have also
shown encouraging outcomes.10 14 18
Thus, we examined children who underwent
endovascular treatment of VOGMs at UCSF to
characterize the clinical and radiological features of
the VOGMs and to determine the predictors of
functional outcome. We also aimed to document
the advances in endovascular approaches used to
treat VOGMs since 1986.
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METHODS
Sample
Patients who underwent endovascular treatment of VOGMs at
UCSF between 1986 and 2013 were included. The UCSF inter-
ventional neuroradiology database was queried for cases involv-
ing “vein of Galen malformation” under an institutional review
board-approved protocol. Sixty-two cases were identiﬁed. Of
these, 41 cases were conﬁrmed to have a VOGM based on the
criteria deﬁned by Lasjaunias et al.12 19 Twenty-one cases repre-
sented non-VOGM diagnoses; often the search term identiﬁed
VOGM in the patient chart not in the context of the diagnosis.
Of the 41 VOGM cases, angiographic images were available for
22. Seven of these cases had digital images on the UCSF Picture
Archiving and Communication System (PACS), while 15 cases
had images on ﬁlm. The angiographic images of 19/41 VOGM
cases were irretrievable, and these cases were assessed through
radiology procedure notes. The demographics and clinical infor-
mation of the sample are presented in table 1.
Imaging evaluation
Two neurointerventional radiologists (SWH and DLC) reviewed
the available angiographic, CT, and MRI studies of the cohort
to characterize the VOGM imaging features using a standardized
record. The diagnostic details, such as the year of diagnosis and
the radiological modality employed to make the diagnosis, were
recorded. Follow-up imaging on the UCSF PACS and radiology
records were also assessed.
Chart review
A single study investigator (MLC) used a standardized data
abstraction form to review all available medical records from
pediatric neurology and neurointerventional radiology depart-
ments. Demographic features, symptoms at presentation,
VOGM classiﬁcation, and other clinical features were recorded.
Details of the endovascular treatment and follow-up informa-
tion were also obtained.
Functional assessment
A single study investigator (MLC) applied the modiﬁed Rankin
Scale (mRS) to assess the functional outcome of the cases at the
last available follow-up.20 The Social Security Death Index was
searched for cases with inadequate chart information.
Statistical analysis
All statistical analyses were conducted using SPSS 21.0 (SPSS
Inc, Chicago, Illinois, USA). Summary and frequency statistics
were applied to analyze the demographic, clinical, and radio-
logical characteristics of the sample. Two-tailed χ2 tests were
applied to assess the associations between case variables and
outcome and clinical and radiological characteristics. χ2 Tests
were also used to assess the differences in endovascular techni-
ques used before and after the arbitrary year 2000. A signiﬁ-
cance threshold of p<0.05 was applied.
RESULTS
Sample demographics and clinical characteristics
Thirty-one male and 10 female patients met the inclusion cri-
teria. The age at ﬁrst presentation and diagnosis ranged from
the ﬁrst day of life to 2.5 years (median=1 day, range=1 day to
2.5 years). More than 50% of the patients in our cohort were
diagnosed before the age of 10 days, and about 7.3% of the
patients were diagnosed after 1 year. The age at ﬁrst angiogram
ranged from 1 day to 6 years (median=120 days). Twenty-nine
per cent of patients were treated before the age of 10 days, and
24.4% were ﬁrst treated after 1 year (table 1).
In total, 65.9% of patients presented with hydrocephalus,
61.0% with congestive heart failure, 34.1% with intracranial
hemorrhage and 29.3% with seizures (table 1). Postnatal CTwas
the most commonly used diagnostic modality, followed by post-
natal MRI, fetal ultrasound, postnatal ultrasound and angiog-
raphy (table 1).
Imaging features
The majority of patients had mixed-type VOGMs (31.7%;
table 2), followed by the mural-type (29.3%) and the choroidal-
type (26.8%). The most common feeding arteries of the VOGM
included the posterior and/or anterior choroidal, posterior cere-
bral, thalamoperforating, anterior cerebral and pericallosal arteries
(table 2). Patent falcine veins, absent straight sinuses, sinus stenosis,
anomalous dural sinuses and venous enlargement were among the
most commonly identiﬁed angiographic features (table 2). Fewer
cases showed complete limbic arches, connections to the deep
Table 1 Patient demographic and clinical information
Demographic factors No (%)
Gender
Male 31 (75.6)
Female 10 (24.4)
Age at first diagnosis
≤10 days 22 (53.7)
11–100 days 5 (12.2)
101–200 days 2 (4.9)
201–365 days 3 (7.3)
>1–2 years 2 (4.8)
>2–3 years 1 (2.4)
Age at first procedure
≤10 days 12 (29.3)
11–100 days 6 (14.6)
101–200 days 6 (14.6)
201–365 days 4 (9.8)
>1–2 years 2 (4.8)
>2–3 years 2 (4.8)
>3–4 years 0 (0.0)
>4–5 years 5 (12.2)
>5 years 1 (2.4)
Diagnostic modality
Postnatal CT 12 (29.3)
Postnatal MRI 9 (22.0)
Fetal ultrasound 6 (14.6)
Angiogram 4 (9.8)
Postnatal ultrasound 3 (7.3)
CHF
Present 25 (61.0)
Absent 12 (29.3)
Seizures
Present 12 (29.3)
Absent 19 (46.3)
Hydrocephalus
Present 27 (65.9)
Absent 8 (19.5)
Intracranial hemorrhage
Present 14 (34.1)
Absent 15 (36.6)
CHF, congestive heart failure.
Neuroimaging
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venous system, alternate pathways of venous drainage, occipital
sinuses, periventricular drainage, venous ectasia, venous reﬂux and
venous sinus thrombus or occlusion. Representative imaging ﬁnd-
ings are shown in ﬁgure 1 and online supplementary ﬁgure 1. The
frequency of imaging features read directly from the angiogram is
listed in online supplementary table 1.
Treatment
The total number of endovascular treatments for each case
ranged from none to seven, with a median of two treatments
(table 3). Only one patient was not treated, and the VOGM
spontaneously resolved.21 One patient received seven total
endovascular treatments, with two of them at UCSF.
In the cohort, 27 patients were treated at UCSF before the
year 2000, and 14 patients were treated at UCSF in the year
2000 or later. There were no differences in total number treated
before and after 2000 (table 3; p=0.219). Transtorcular
approaches were not used after 2000. There was no difference
between the frequencies of transarterial (p=0.919) or transve-
nous approaches before and after 2000 (p=0.604).
The embolic agents used in the treatment of the cohort
included: coils, silk sutures, N-butyl cyanoacrylate, polyvinyl
alcohol (PVA), liquid coils, and platinum wire (table 3). The use
of silk sutures differed signiﬁcantly before and after 2000
(p=0.014). No silk sutures, PVA, or platinum wire were used in
treatment after 2000.
Associations between imaging and clinical characteristics
Next, we looked for associations between the imaging and clin-
ical characteristics by stratifying the patients into three groups
based on the degree of VOGM venous varix dilatation (mild,
moderate, or severe). There were nine cases in the mild group,
11 in the moderate group and four cases in the severe group.
We found signiﬁcant differences in frequency between groups in
the presence of venous reﬂux (p=0.006; moderate > mild=se-
vere), the number of feeding connections (p<0.001; moderate
> mild > severe), the presence of seizures (p=0.034; mild
> moderate > severe), and the presence of a pericallosal artery
feeder (p=0.036; moderate > mild=severe). The severity of
the VOGM dilatation was not associated with CHF (p=0.337),
hydrocephalus (p=0.523), or intracranial hemorrhage
(p=0.060).
χ2 Tests were also applied to compare the characteristics of
the choroidal-, mural- or mixed-type VOGMs. There were
11 cases in the choroidal group, 12 in the mural group, and 13
in the mixed group. Signiﬁcant differences in frequency were
found between groups in the presence of thalamoperforating
artery feeders (p=0.014; mixed > choroidal > mural), pres-
ence of anterior cerebral artery feeders (p=0.010; choroidal >
mixed > mural), and number of feeding connections
(p=0.021; mixed > choroidal > mural).
In addition, we explored the relationship between seizures
and intracranial calciﬁcations secondary to high-pressure
damage. Of the ﬁve patients with evident calciﬁcations on
imaging, four presented with seizures; the seizure status of the
remaining individual was unknown. The embolization proce-
dures for each of these patients were performed at 3 months,
19 months, 2 years, 4 years, and 4 years. Of the ﬁve patients,
embolization was complete in three, partially complete in one,
and incomplete in the remaining one patient. Whether the calci-
ﬁcations and seizures were affected by the embolization proce-
dures is unknown. On neurologic follow-up, however, four of
these ﬁve patients had developmental delays in motor and cog-
nitive domains after their procedures.
Outcome based on chart review
Median follow-up for chart review was 3 years, range=0–
23 years. Of the patients (table 3), 9/36 (22.0% of the total
number of patients) are known to have died (mRS=6). In total,
19.5% were neurologically normal on last follow-up (mRS=0).
Another 24.4% of cases (mRS=1 and 2) were mildly affected
and remained functional. The remaining 22.0% were moder-
ately or severely affected (mRS=3–5). The ﬁve (12.2%) remain-
ing patients are known to be living based on the Social Security
Death Index. There were no differences in mRS scores between
the group treated before and after the year 2000 (p=0.913).
Of the 20 patients who were diagnosed on the ﬁrst day of
life, 11 survived (55%). We compared those who survived with
those who died using a χ2 test on all clinical and radiological
features. Venous sinus dilatation (p=0.016) and the presence of
a straight sinus (p=0.038) were associated with the patients
who did not survive.
A worse ﬁnal mRS was signiﬁcantly associated with younger
age at ﬁrst diagnosis (p=0.028), the presence of seizures
(p=0.008) and CHF (p=0.044), incomplete or limited ﬁstula
thrombosis after treatment (p=0.010), and the use of PVA as
the embolic material for endovascular treatment (p=0.015). All
nine patients with a mRS of 6 were diagnosed on the ﬁrst day
of life, though three cases also diagnosed on the ﬁrst day of life
had mRS scores of 0, 2, and 4. Final mRS was not predicted by
the year of treatment (p=0.151) or angioarchitecture subtype
(p=0.534). Death was associated with younger age at ﬁrst treat-
ment procedure (p=0.017), the presence of CHF (p=0.017)
and hydrocephalus (p=0.037), the presence of a straight sinus
(p=0.027), the presence of a posterior inferior cerebellar
feeding artery (p=0.002), incomplete or limited ﬁstula obliter-
ation (p=0.004), and lack of ﬁstula thrombosis on follow-up
imaging (p=0.01).
Table 2 Imaging features of the vein of Galen malformations
Diagnostic features No (%)
Choroidal 11 (26.8)
Mural 12 (29.3)
Mixed 13 (31.7)
Common feeding arteries
Choroidal artery 28 (68.3)
Posterior cerebral artery 19 (46.3)
Thalamoperforatoring artery 18 (43.9)
Anterior cerebral artery 8 (19.5)
Pericallosal artery 6 (14.6)
Radiological features
Venous enlargement 22 (53.7)
Anomalous dural sinus 20 (48.8)
Patent falcine vein 19 (46.3)
Sinus stenosis 16 (39.0)
Absent straight sinus 13 (31.7)
Venous ectasia 12 (29.3)
Venous reflux 11 (26.8)
Limbic arch 10 (24.4)
Alternate pathways of venous drainage 9 (22.0)
Connection to deep venous system 6 (14.6)
Occipital sinus 5 (12.2)
Periventricular drainage 5 (12.2)
Venous sinus thrombus or occlusion 4 (9.8)
Neuroimaging
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In total, 41.2% of 17 cases had radiological evidence of
atrophy at baseline and 64.3% of 14 cases had atrophy after
treatment. Neither the presence of atrophy at baseline
(p=0.061) nor after treatment (p=0.117) was predictive of
functional outcome.
At the last follow-up, the ﬁnal obliteration of the VOGM was
complete in 62.5% of valid cases, partial in 12.5% and incom-
plete in 25.0% (N=32). Thrombosis on follow-up imaging was
achieved in 72.7% of valid cases. White matter calciﬁcations
were found in 31.3% of cases on CT. Distal migration of the
embolization coils occurred in three cases (7.3%).
DISCUSSION
In this study of 41 children treated for their VOGMs, we have
shown that current endovascular embolization procedures allow
up to half of patients with the condition to live functionally
Figure 1 Representative imaging studies. (A) Sagittal T1-weighted MR image demonstrating the dilated prosencephalic vein and persistence of the
falcine sinus. (B) Maximum intensity pixel MR angiographic image demonstrating multiple enlarged arterial branches from the anterior and posterior
cerebral arteries coalescing on the lateral margins of the dilated recipient vein. (C–F) Composite DSA capturing early (C and E) and delayed
(D and F) contrast bolus images. Anterior–posterior (C) and lateral (E) images of a right vertebral arterial injection demonstrate enlarged ipsilateral
posterior–lateral choroidal and perimesencephalic branches as well as a smaller thalamoperforating branch coalescing on the anterior–lateral aspect
of the recipient vein. Anterior–posterior (D) and lateral (F) images of a left internal carotid artery injection show similarly enlarged posterior–lateral
choroidal and perimesencephalic branches arising from the ipsilateral posterior cerebral artery, and smaller branches from the distal pericallosal
artery. The lateral projection (F) also demonstrates the dilated prosencephalic vein and persistence of the falcine and occipital sinuses.
Neuroimaging
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normal or near-normal lives. Mixed-type VOGMs were the
most commonly seen subtype in our sample. The most com-
monly observed radiological characteristics included choroidal
and posterior cerebral artery feeders, patent falcine veins and
sinus stenosis. We showed that poor outcomes were associated
with early age of diagnosis, seizures, CHF, and hydrocephalus at
presentation, and incomplete embolization. We have also docu-
mented changes in the usage of endovascular techniques and
embolization materials since 1986.
In our sample, the survival rate after embolization was
78.0%. The overall survival and technical success rates of endo-
vascular treatments for VOGMs from other studies also
approach 80%,11 22–24 suggesting that these approaches are safe
and effective. Our observation that many of the children are
neurologically normal or near-normal at last follow-up is con-
sistent with previous reports.10 17 25 Further, early presentation
with CHF and seizures was an important predictor of morbidity
and mortality in our sample, and the prognosis for patients with
VOGMs presenting with CHF in the neonatal period remains
poor.5 6 17 Childhood seizures have been previously associated
with cortical injury and poor outcomes, as they may exacerbate
neural injury and impair neurodevelopment.26 27 Therefore, we
have conﬁrmed the previously identiﬁed markers of prognosis
and overall efﬁcacy of endovascular embolization techniques for
treating VOGMs.
In contrast to past studies,28 however, the mixed-type VOGM
was the most common subtype in our sample. We did not ﬁnd
choroidal-type VOGMs to be associated with greater functional
disability or mortality.17 25 Perhaps this ﬁnding is associated
with the use of transvenous embolization approaches at UCSF
in cases unsuitable for, or refractory to, transarterial
approaches,29 such as in perinatal, choroidal-type VOGMs. The
use of this approach, however, remains controversial.7 14 30 A
major difference between our data and the Bicetre data is that
67/317 (21%) of their patients underwent no angiography/
embolization.10 Since diagnostic angiography was not under-
taken by the Bicetre group unless an intervention was planned,
the true choroidal:mural ratio for that population is unknown.
It is quite possible that patients with choroidal type VOGMs
were preferentially not treated at Bicetre because they are
sicker at baseline and thus would be excluded from interven-
tion according to that institution’s well-described clinical
exclusion criteria. The use by our institution of transvenous
embolization (our preferred approach rather than choroidal
VOGM) may thus reﬂect our treatment of patients who other-
wise would not have been treated at Bicetre. We also favor coil
over liquid embolic embolization in patients with heart failure,
as there is a lower probability of coil migration to the lungs
and thus a smaller chance of worsening heart failure, in con-
trast to previous studies.10 Nonetheless, the total number of
required procedures is decreasing over time, and the transarter-
ial approach is currently more commonly employed.25 28 Our
rate of complete thrombosis on follow-up imaging in this
sample was 62.5%, an improvement on previous reports.10
Overall, endovascular treatment has been successful at obliter-
ating the VOGM shunts with fewer side effects than neurosur-
gical approaches.15 31 32
The generalizability of our results is limited by the small
sample size. We were unable to identify radiological character-
istics of some cases directly from imaging because records were
not available in 19/41 of our patients. With improvements in
electronic medical records and patient tracking, however, we
hope that future studies will be able to acquire more complete
clinical information on patients with VOGMs, including poten-
tially signiﬁcant delayed effects of the x-rays used for image-
guided therapy.33 Moreover, the mRS outcome score that we
used in this study is not a sensitive measure of patient functional
disability and quality of life. Survey-based analyses using stan-
dardized instruments may be important in understanding the
detailed outcomes of these patients.17
We have described a cohort of patients with VOGMs
treated with endovascular approaches at UCSF. As these tech-
niques are reﬁned and improved, further understanding of the
pathology of VOGMs will guide treatment decisions for each
patient. VOGMs continue to be challenging vascular malfor-
mations to manage, but neurointerventional approaches allow
many children with these malformations to live near-normal
lives.
Table 3 Treatment approaches and embolic materials employed
prior to and after the year 2000. P-values compare between groups
treated prior to and following the year 2000.
Total No (%) Prior to 2000 After 2000
P-value
Total treatments P=0.266
0 1 (2.4) 1 (3.7) 0 (0.0)
1 10 (24.4) 7 (25.9) 3 (21.4)
2 16 (39.0) 7 (25.9) 9 (64.3)
3 5 (12.2) 3 (11.1) 2 (14.3)
4 3 (7.3) 3 (11.1) 0 (0.0)
5 4 (9.8) 4 (14.8) 0 (0.0)
6 1 (2.4) 1 (3.7) 0 (0.0)
7 1 (2.4) 1 (3.7) 0 (0.0)
Transarterial approach P=0.902
0 5 (12.8) 4 (15.4) 1 (7.7)
1 22 (56.4) 14 (53.8) 8 (61.5)
2 8 (20.5) 5 (19.2) 3 (23.1)
3 3 (7.7) 2 (7.7) 1 (7.7)
4 1 (2.6) 1 (3.8) 0 (0.0)
Transvenous approach P=0.604
0 14 (38.9) 9 (37.5) 5 (41.7)
1 14 (38.9) 8 (33.3) 6 (50.0)
2 4 (11.1) 3 (12.5) 1 (8.3)
3 3 (8.3) 3 (12.5) 0 (0.0)
4 1 (2.8) 1 (4.2) 0 (0.0)
Transtorcular approach P=0.076
0 28 (77.8) 16 (66.7) 12 (100.0)
1 7 (19.4) 7 (29.2) 0 (0.0)
2 1 (2.8) 1 (4.2) 0 (0.0)
Embolic agent
Coils 38 (92.6) 25 (100.0) 13 (100.0) NA
Silk sutures 8 (19.5) 8 (38.1) 0 (0.0) P=0.014
NBCA 5 (12.2) 2 (9.5) 3 (25.0) P=0.233
PVA 5 (12.2) 5 (23.8) 0 (0.0) P=0.067
Liquid coils 1 (2.4) 0 (0.0) 1 (7.7) P=0.197
Platinum wire 1 (2.4) 1 (4.8) 0 (0.0) P=0.425
mRS P=0.913
0 8 (19.5) 6 (24.0) 2 (18.2)
1 5 (12.2) 4 (16.0) 1 (9.1)
2 5 (12.2) 3 (12.0) 2 (18.2)
3 2 (4.9) 1 (4.0) 1 (9.1)
4 2 (4.9) 2 (8.0) 0 (0.0)
5 5 (12.2) 3 (12.0) 2 (18.2)
6 9 (22.0) 6 (24.0) 3 (27.3)
p Values for the comparison of groups treated before and after the year 2000.
mRS, modified Rankin Scale; NBCA, N-butyl cyanoacrylate; PVA, polyvinyl alcohol.
Neuroimaging
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